



Transforming Addiction Therapeutics

January 2025

Forward-Looking Statements

Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business and projects; (iv) execution of the Company’s vision and growth strategy and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.



DemeRx is a clinical-stage biotechnology company, based in Miami, developing next-generation addiction medicines with first-in-class profiles.

DemeRx is developing DMX-1001 (oral noribogaine) for the treatment of Alcohol Use Disorder (AUD), a condition that affects 29 million people in the U.S.

DMX-1001 enhances neuroplasticity, allowing the brain to repair neural circuits damaged by chronic heavy drinking and potentially offering a more effective solution than existing pharmacological treatments for AUD.

DemeRx has commenced a Phase 1b clinical trial to assess pharmacokinetics, pharmacodynamics and safety of DMX-1001 in 60 healthy volunteers, anticipating top-line data in Q1 2025.

This milestone will allow DemeRx to initiate a Phase 2a trial in Q2'25 with 120 participants, aiming to validate the efficacy of an oral dose formulation.

DemeRx has secured an IP portfolio of 24 U.S. patents and 17 international patents, with 8 patent applications.

DemeRx's experienced leadership team includes pioneers in psychedelic medicine and addiction neurobiology, alongside seasoned biotech executives from prominent companies like Reckitt Benckiser Pharmaceuticals and Opiant Pharmaceuticals, the latter of which was acquired by Indivior for \$122 million.

Our leadership team is highly experienced in addiction medicine and pharmaceutical development



Deborah C. Mash PhD
Chief Executive Officer and Founder

Mark Ellison PhD
Chief Development Officer

E. Douglas Kramer MD
Vice President of Clinical and Regulatory Affairs

John Thomas CPA
Chief Financial Officer

World-renowned expert in addiction treatment and the discovery and research of noribogaine for substance use disorders.

Proven record of driving start-ups and small pharma companies to successful product development and market launch.

Highly regarded medical professional with a background in drug R&D, regulatory affairs and addiction treatment.

Seasoned CFO in the biotechnology and medical device industries, with a record of success in public and private companies.



DemeRx's pipeline in substance use disorders

Our focus is on DMX-1001 in alcohol use disorder



Clinical and preclinical pipeline

Indication	Preclinical	Phase 1	Phase 2	Anticipated Milestone
Alcohol use disorder (AUD)	DMX-1001 noribogaine			Ph 1b data expected H1 2025
Substance use disorders (SUD)	DMX-100 noribogaine			
Substance use disorders (SUD)	DMX-2001 Azepinoindoles DMX-3001 Spiroindamines			

Alcohol use disorder is a major cause of harm

Prevalence, risks and consequence of alcohol use disorder (AUD)

Alcohol Use Disorder People with AUD

29 million | **400 million**
United States | Worldwide

AUD Societal Cost Yearly in the U.S.

\$250 billion

Alcohol-Related Deaths

178,307 | **2.6 million**
Annual deaths (U.S.) | Annual deaths (Worldwide)

Emergency Department Visits Yearly in the U.S.

4,126,082
All-alcohol related

STAT
HEALTH
By the numbers: America's alcohol-related health problems are rising fast

By Isabella Cueto and J. Emory Parker June 27, 2024

And yet...


less than 5% of those affected by AUD in the U.S. **receive medication.**

Sources: 2023 NSDUH Tables 2.26A&B; 2021 HCUP-NEDS; 2020-2021 CDC ARDI; World Health Organization
*Acute and chronic alcohol-related deaths do not add to the total due to rounding

For those on treatment for AUD, 60% will relapse to hazardous drinking within 6 months

Chronic relapse is driven by **lasting negative neuroplastic changes to the addiction cycle in the brain** from ongoing alcohol use.

- Existing approved medications primarily address symptoms which:
 - Modulate single target chemical imbalances in the brain.
 - Conditions aversion to alcohol in severe alcoholics.
- These approaches do not promote lasting, disease-modifying changes. This fact may explain the high relapse rates.



Significant market for improved AUD therapeutic treatment



Significant opportunity to treat AUD globally....


... and in the U.S. where 1.4m seek Rx help

Global alcohol use disorder treatment market

- 2023 Market Value: \$700 million
- 2033 Projected Value: \$1,300 million
- 2023-2033 Growth Rate: CAGR of 6.4%

Key drivers

- Increasing rates of alcohol use and binge drinking
- Universal impact across all demographics
- Larger market than for other addictions
- Increase in treatment-seeking frequency



Against this opportunity, we are developing DMX-1001...

Source: Future Market Insights, Oct 2024

DMX-1001 represents a groundbreaking therapeutic seeking to break the addictive cycle of AUD

DMX-1001 (oral noribogaine) employs **polypharmacology** and **neuroplasticity** for fast and lasting effect



First-in-Class neuroplastogen

Brings two circuit level mechanisms into one novel candidate for alcohol and other drug use disorders.

Affects multiple CNS targets

Engages multiple neurotransmitters within the addiction circuitry of the brain to reset chemical imbalances.

Potential to stimulate neuronal repair

Modulates neuroplasticity to enhance dopamine pathways.
Supports recovery of brain regions affected by alcohol and drug misuse.


Favorable side effect profile

In clinical Phase 1, noribogaine was safe and well tolerated. Noribogaine has no euphoric effects or potential for abuse.


Animal models of alcoholism provide proof of concept which support DMX-1001 as a first-in-class AUD candidate



Noribogaine IP* dose-dependently reduced alcohol intake in alcohol preferring rats




Administration of 5 mg/kg noribogaine IP suppressed alcohol intake in high-alcohol-drinking rats



In clinical Phase 1 and preclinical trials, noribogaine was well tolerated with no euphoric effects or potential for abuse.

Amir H. Rezvani, Ph.D., (unpublished data)
*intraperitoneal injection

DMX-1001 development roadmap: key milestones over the next 18 months



*Investigational New Drug Application (IND)

DemeRX has developed an extensive patent portfolio around DMX-1001



Patents provide protection across geographies

- The USPTO has granted 24 patents on these applications.
- An additional 17 patent grants and applications target the international market.
- DemeRX invested \$5.2 million to secure patents.

Company patents fall into four broad categories

01 Composition of matter

02 Combination therapies

03 Synthetic processes and formulations

04 Methods of use

Further eight patents currently under review



Join us in Transforming Lives

WWW.DEMERX.COM





Contact



+1 786-347-3500



info@demerx.com

WWW.DEMERX.COM